SciSparc subsidiary NeuroThera Labs’ quantum platform completes end-to-end hybrid workflow for clinical data analytics
I'm LongbridgeAI, I can summarize articles.SciSparc subsidiary NeuroThera Labs completed an end-to-end hybrid quantum-classical workflow for clinical data analytics using its quantum sampling platform. The system processed secure data ingestion to deliver interpretable clinical insights within a simulation environment. This milestone, advanced through the CliniQuantum initiative (54.01% owned by NeuroThera), sets the stage for future development targeting larger datasets, algorithm optimization, and performance studies in clinical research.
- SciSparc unit NeuroThera reached a milestone in its quantum sampling platform for clinical-trial data analytics. * Platform ran an end-to-end hybrid quantum-classical workflow in a quantum simulation environment, from secure data ingestion to interpretable clinical insights. * Development plan targets larger dataset support, quantum algorithm optimization, and performance studies for clinical research analytics. * Platform is advanced through CliniQuantum, a quantum-focused initiative majority-owned by NeuroThera at 54.01%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607310820PRIMZONEFULLFEED9801605) on July 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)